Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses

David Sanford, MD, Francesco LoCoco, MD, Miguel A. Sanz, MD PhD, Eros Di Bona, MD, Steven Coutre, MD, Jessica K. Altman, MD, Meir Wetzler, MD, Steven L. Allen, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 3751.

https://doi.org/10.1182/blood.V124.21.3751.3751

Published: 2014

Journal Articles

Arsenic Trioxide-Based Therapy Of Relapsed Acute Promyelocytic Leukemia: Updated Results Of The European Registry Of Relapsed APL (PROMYSE)

Eva Lengfelder, MD, Francesco Lo-Coco, MD, Lionel Ades, Pau Montesinos, David Grimwade, MD, PhD, Bhuvan Kishore, Safaa Ramadan, MD, Maria Pagoni, Massimo Breccia, Concha Rivas, MD, José Gonzáles-Sanmiguel, MD, Anne Schmidt, Jean-Francois Lambert, Wolf-Karsten Hofmann, MD, Maria Cristina Sauerland, Pierre Fenaux, Miguel Sanz

Blood (2013) 122 (21): 1406.

https://doi.org/10.1182/blood.V122.21.1406.1406

Published: 2013

Journal Articles

How I treat hematologic emergencies in adults with acute leukemia

Tsila Zuckerman, Chezi Ganzel, Martin S. Tallman, Jacob M. Rowe

Blood (2012) 120 (10): 1993–2002.

https://doi.org/10.1182/blood-2012-04-424440

Published: 2012

Journal Articles

Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group

Blood (2011) 118 (21): 425.

https://doi.org/10.1182/blood.V118.21.425.425

Published: 2011

Journal Articles

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

Blood (2010) 116 (25): 5650–5659.

https://doi.org/10.1182/blood-2010-06-288613

Published: 2010

Journal Articles

New Cases of Acute Promyelocytic Leukemia Treatment by Arsenic Trioxide Alone and Their Long Term Follow up

Ardeshir Ghavamzadeh, Kamran Alimoghaddam, MD, Shahrbano Rostami, MSc, Seyed Hamidolah Ghaffari, Mohamad Jahani, Mahdi Jalili, MD, Seyed Asadollah Mousavi, MD, Masood Iravani, MD, Eisa Baybordi, MD, Babak Bahar, MD, Nassrin Alizadeh

Blood (2010) 116 (21): 506.

https://doi.org/10.1182/blood.V116.21.506.506

Published: 2010

Journal Articles

Risk Factors and Clinical Outcome of Central Nervous System (CNS) Leukemia In Patients with Acute Promyelocytic Leukemia (APL) on Long-Term Oral Arsenic Trioxide Maintenance.

Wing Y Au, Cyrus Kumana, MD, Yok lam Kwong, MD

Blood (2010) 116 (21): 1082.

https://doi.org/10.1182/blood.V116.21.1082.1082

Published: 2010

Journal Articles

Arsenic Trioxide as First Line Therapy for New Case of APL, Results and Long Term Follow up.

Ardeshir Ghavamzadeh, Kamran Alimoghaddam, MD, Seyed Hamidolah Ghaffari, Shahrbano Rostami, Mohamad Jahani, Seyed Asadollah Mossavi, Massoud Iravani, Ali Khodabandeh, Eissa Baybordi, Babak Bahar, Mahdi Jalili

Blood (2009) 114 (22): 1023.

https://doi.org/10.1182/blood.V114.22.1023.1023

Published: 2009

Journal Articles

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Miguel A. Sanz, David Grimwade, Martin S. Tallman, Bob Lowenberg, Pierre Fenaux, Elihu H. Estey, Tomoki Naoe, Eva Lengfelder, Thomas Büchner, Hartmut Döhner, Alan K. Burnett, Francesco Lo-Coco

Blood (2009) 113 (9): 1875–1891.

https://doi.org/10.1182/blood-2008-04-150250

Published: 2009

Journal Articles

Treatement of New Cases of Acute Promyelocytic Leukemia by Arsenic Trioxide Whitout ATRA +/− Chemotherapy and Long Term Follow up of Patients

Ardeshir Ghavamzadeh, Kamran Alimoghaddam, MD, Seyed Hamidolah Ghaffari, Shahrbano Rostami, Mohamad Jahani, Rohollah Hosseini, Massoud Iravani, Seyed Asadollah Mossavi, Ali Khodabandeh, Babak Bahar, Eissa Baybordi, Mehrangiz Tootonchi, Ezat Eini, Zahra Nasri Moghadam, Fakhri Afshar, Parvin Radsafa

Blood (2008) 112 (11): 140.

https://doi.org/10.1182/blood.V112.11.140.140

Published: 2008

Journal Articles

All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As 2 O 3 ) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Apostolia-Maria Tsimberidou, MD, PhD, Hagop Kantarjian, MD, Susan O’Brien, MD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Daniel Jones, MD, Sherry Pierce, RN, Mark Brandt, BA, Michael Keating, MB, BS, Estey Estey, MD

Blood (2007) 110 (11): 1834.

https://doi.org/10.1182/blood.V110.11.1834.1834

Published: 2007

Journal Articles

Treatment of Non-APL Acute Myelogenous Leukemia with Intravenous Arsenic Trioxide Plus Ascorbic Acid.

Dan Douer, MD, Kristy Watkins, R.N., Robert Louie, PhramD, Ilene Ceil Weitz, M.D., Ann Mohrbacher, M.D., Lisa Mark, P.A., Alexandra M. Levine, M.D.

Blood (2006) 108 (11): 1959.

https://doi.org/10.1182/blood.V108.11.1959.1959

Published: 2006

Journal Articles

Treatment of Non-APL Acute Myelogenous Leukemia with Intravenous Arsenic Trioxide Plus Ascorbic Acid.

Dan Douer, MD, Kristy Watkins, RN, Robert Louie, PharmD, Ilene Weitz, MD, Ann M. Mohrbacher, MD, Lisa Mark, PA-C, Alexandra Levine, MD

Blood (2005) 106 (11): 4603.

https://doi.org/10.1182/blood.V106.11.4603.4603

Published: 2005

Journal Articles

Arsenic Trioxide (AS 2 O 3 ) Therapy for Relapsed Acute Promyelocytic Leukemia (APL): Comparison with a Historic Control Combining All- Trans Retinoic Acid (ATRA) Plus Intensive Chemotherapy.

Xavier Thomas, Arnaud Pigneux, Emmanuel Raffoux, Francoise Huguet, Denis Caillot, Agnes Guerci, Aspasia Stamatoullas, Oumedaly Reman, Francoise Isnard, Francois Dreyfus, Nicole Gratecos, Marc Bernard, Yazid Arkam, Pierre Fenaux

Blood (2005) 106 (11): 895.

https://doi.org/10.1182/blood.V106.11.895.895

Published: 2005

Journal Articles

Use of All-Transretinoic Acid (ATRA) + Arsenic Trioxide (ATO) To Eliminate or Minimize Use of Chemotherapy (CT) in Untreated Acute Promyelocytic Leukemia (APL).

Elihu H. Estey, MD, Guillermo Garcia-Manero, MD, Alexandra Ferrajoli, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, Hagop Kantarjian, MD

Blood (2004) 104 (11): 393.

https://doi.org/10.1182/blood.V104.11.393.393

Published: 2004

Journal Articles

Treatment of Acute Myelogenous Leukemia (non-APL) with Intravenous Trisenox® (Arsenic Trioxide) and Ascorbic Acid: Preliminary Results.

Dan Douer, MD, Kristy Watkins, RN, Robert Louie, PharmD, Ilene Weitz, MD, Ann Mohrbacher, MD, Alexandra M. Levine, MD

Blood (2004) 104 (11): 1815.

https://doi.org/10.1182/blood.V104.11.1815.1815

Published: 2004

NARROW

Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses

Arsenic Trioxide-Based Therapy Of Relapsed Acute Promyelocytic Leukemia: Updated Results Of The European Registry Of Relapsed APL (PROMYSE)

How I treat hematologic emergencies in adults with acute leukemia

Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

New Cases of Acute Promyelocytic Leukemia Treatment by Arsenic Trioxide Alone and Their Long Term Follow up

Risk Factors and Clinical Outcome of Central Nervous System (CNS) Leukemia In Patients with Acute Promyelocytic Leukemia (APL) on Long-Term Oral Arsenic Trioxide Maintenance.

Arsenic Trioxide as First Line Therapy for New Case of APL, Results and Long Term Follow up.

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Treatement of New Cases of Acute Promyelocytic Leukemia by Arsenic Trioxide Whitout ATRA +/− Chemotherapy and Long Term Follow up of Patients

All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As 2 O 3 ) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Treatment of Non-APL Acute Myelogenous Leukemia with Intravenous Arsenic Trioxide Plus Ascorbic Acid.

Treatment of Non-APL Acute Myelogenous Leukemia with Intravenous Arsenic Trioxide Plus Ascorbic Acid.

Arsenic Trioxide (AS 2 O 3 ) Therapy for Relapsed Acute Promyelocytic Leukemia (APL): Comparison with a Historic Control Combining All- Trans Retinoic Acid (ATRA) Plus Intensive Chemotherapy.

Use of All-Transretinoic Acid (ATRA) + Arsenic Trioxide (ATO) To Eliminate or Minimize Use of Chemotherapy (CT) in Untreated Acute Promyelocytic Leukemia (APL).

Treatment of Acute Myelogenous Leukemia (non-APL) with Intravenous Trisenox® (Arsenic Trioxide) and Ascorbic Acid: Preliminary Results.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only